Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Non-Current Assets (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Non-Current Assets for 6 consecutive years, with $43.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 30.66% to $43.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $197.2 million through Dec 2025, down 26.06% year-over-year, with the annual reading at $43.1 million for FY2025, 30.66% down from the prior year.
  • Non-Current Assets for Q4 2025 was $43.1 million at Relay Therapeutics, down from $46.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $81.4 million in Q3 2022, with the low at $28.9 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $56.3 million, with a median of $60.9 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 151.64% in 2022, then tumbled 30.66% in 2025.
  • Over 5 years, Non-Current Assets stood at $32.2 million in 2021, then surged by 149.27% to $80.3 million in 2022, then fell by 7.96% to $73.9 million in 2023, then decreased by 15.95% to $62.1 million in 2024, then crashed by 30.66% to $43.1 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $43.1 million, $46.0 million, and $48.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.